Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment-Reference-Cited by-同舟云学术

Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment

Published:2021-12 Issue: Volume:159 Page:105-112
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Buttiron Webber Tania^ORCID,Provinciali Nicoletta^ORCID,Musso Marco,Ugolini Martina^ORCID,Boitano Monica,Clavarezza Matteo,D'Amico Mauro,Defferrari Carlotta,Gozza Alberto,Briata Irene Maria^ORCID,Magnani Monica,Paciolla Fortuna,Menghini Nadia,Marcenaro Emanuela^ORCID,De Palma Raffaele,Sacchi Nicoletta,Innocenti Leonello,Siri Giacomo,D'Ecclesiis Oriana,Cevasco Isabella,Gandini Sara^ORCID,DeCensi Andrea

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference33 articles.

1. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study;Kuderer;Lancet,2020

2. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study;Lee;Lancet Oncol,2020

3. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine;Polack;N Engl J Med,2020

4. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study;Monin;Lancet Oncol,2021

5. Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients;Palich;Ann Oncol,2021

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung Cancer;Vaccines;2024-06-26

2. Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study;International Journal of Clinical Oncology;2024-02-21

3. SARS-CoV-2 vaccination willingness and humoral vaccination response in radiation oncology patients;Vaccine;2024-02

4. Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab Treatment in Patients with Advanced Ovarian Cancer;Cancer Research Communications;2023-12-20

5. Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study;2023-11-29